METHYLPHENIDATE / DEXMETHYLPHENIDATE
Adhansia XR*, Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Jornay PM**, Metadate CD, Metadate ER, Relexxii [Methylphenidate ER (OSM)], Methylin, Methylin-ER, Quillivant XR, QuilliChew ER, Ritalin, Ritalin LA, Ritalin-SR, Focalin, Focalin XR (Methylphenidate and Dexmethylphenidate)

*These medications are included in this policy but are not available in the market as of yet
** Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication

RATIONALE FOR INCLUSION IN PA PROGRAM

Background
Methylphenidate is a DEA schedule II drug and a CNS stimulant which is FDA approved for attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD) and narcolepsy. The exact mechanism by which methylphenidate acts is unknown; however, it presumably increases dopamine and norepinephrine levels in the brain (1-16). Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (17).

For patients 22 years of age and older prior authorization and review is required for both diagnosis and quantity requested. For patients 21 years of age and younger, review is required if the total daily dose exceeds the FDA recommended daily limit.

Regulatory Status
The products addressed by this policy are FDA-approved for use in one or more of the following conditions: attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD) and narcolepsy (1-16).

Off Label Uses:
Methylphenidates can be used as adjunctive therapy in the treatment of resistant depression (17).

Methylphenidate has a boxed warning regarding the high potential of abuse and addiction and should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic and or abusive use can lead to marked tolerance and psychological dependence. Quantity limits based on the FDA-approved dosage guidelines help to reduce abuse, addiction, and dose dependent adverse effects (1-16).
METHYLPHENIDATE / DEXMETHYLPHENIDATE

Adhansia XR*, Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Jornay PM**, Metadate CD, Metadate ER, Relexxii [Methylphenidate ER (OSM)], Methylin, Methylin-ER, Quillivant XR, QuilliChew ER, Ritalin, Ritalin LA, Ritalin-SR, Focalin, Focalin XR (Methylphenidate and Dexmethylphenidate)

*These medications are included in this policy but are not available in the market as of yet
** Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication

Contraindications with the use of methylphenidate include marked anxiety, tension, agitation, glaucoma, tics, or a family history or diagnosis of Tourette’s syndrome. Methylphenidate is contraindicated in patients currently using or within 2 weeks of using an MAO inhibitor (1-16).

Safety and efficacy has not been established for Adhansia XR, Daytrana, and Jornay PM in children under six years old (2,15-16).

Summary

Methylphenidate is a DEA schedule II drug and a CNS stimulant which is FDA approved for attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD) and narcolepsy. Dexmethylphenidate is approved for the treatment of ADHD. The exact mechanism by which methylphenidate acts is unknown; however, it is presumed to increase dopamine and norepinephrine levels in the brain. Methylphenidate has a boxed warning for a high potential of abuse and addiction (1-16).

Prior approval is required to ensure the safe, clinically appropriate and cost effective use of methylphenidate and dexmethylphenidate while maintaining optimal therapeutic outcomes.

References

METHYLPHENIDATE / DEXMETHYLPHENIDATE
Adhansia XR*, Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Jornay PM**, Metadate CD, Metadate ER, Releexxi [Methylphenidate ER (OSM)], Methylin, Methylin-ER, Quillivant XR, QuilliChew ER, Ritalin, Ritalin LA, Ritalin-SR, Focalin, Focalin XR (Methylphenidate and Dexmethylphenidate)

*These medications are included in this policy but are not available in the market as of yet
** Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication